---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-318469"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2025-12-15T23:59:59+00:00"
generated_at: "2026-05-16T13:16:17.226293+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "medium"
source: SEC EDGAR
---

# Kyverna reports positive topline data from Phase 2 KYSA-8 trial of miv-cel in stiff person syndrome

## Summary
- Positive topline data from registrational Phase 2 trial of miv-cel (KYV-101) in stiff person syndrome (SPS).
- Trial KYSA-8 evaluates fully human autologous CD19 CAR T-cell therapy with CD28 co-stimulation.
- Company to host conference call on Dec 15, 2025 at 8:00 AM ET to discuss results.

## SEC filing metadata
- accession: 0001193125-25-318469
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2025-12-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000119312525318469/0001193125-25-318469-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000119312525318469/d33692d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-318469
- JSON: https://secwatch.observer/filing/0001193125-25-318469.json
- Plain text: https://secwatch.observer/filing/0001193125-25-318469.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.